Surface Ophthalmics, Inc.

PLEASANTON, CA · Founded 2017 · Biotech · Private

Pharmaceutical therapeutics for ocular diseases

Claim this profile

Follows are private to you and power your alerts

Updated · surfaceophthalmics.com

Sector
Biotech
Headquarters
PLEASANTON, CA
Founded
2017
Latest Form D
$5.8M, Jun 2021
Total capital
$20.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$20.8M
2 Form D · last Jun 2021
65 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
4
13 pending · first 2023
Rank in peer group#293 of 1449

Capital timeline

2018201920202021FEDERAL ↑EQUITY ↓Cumulative $20.8M1st Form D$15M2nd Form D$5.8M
2018201920202021FEDERAL ↑EQUITY ↓Cumulative $20.8M1st Form D$15M2nd Form D$5.8M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$5.8M
  • Private capital raisedForm D · SEC · 1st filing$15M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#293 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Richard LindstromResearcherDirectorLinked by 2 patents
  • Kamran HosseiniResearcherExecutive Officer, DirectorLinked by 1 patent
  • Adrienne Andy GravesDirectorNamed in SEC Form D filings
  • J. Andy CorleyDirectorNamed in SEC Form D filings
  • Mark BaumDirectorNamed in SEC Form D filings
  • Perry Andy SternbergExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
  • Shelley Andy ThunenDirectorNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 17
Show all 17 patent records
  • Eye Drop Formulations Containing Chondroitin Sulfate For Relieving Ocular Pain Or DiscomfortJan 8, 2026 · Application 19329207Pending
  • Use Of Chondroitin Sulfate For Relieving Ocular PainOct 14, 2025 · US 12,440,510Granted
  • Use Of Chondroitin Sulfate For Relieving Ocular PainMay 27, 2025 · US 12,310,981Granted
  • Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseAug 27, 2024 · US 12,070,442Granted
  • Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseSep 26, 2023 · US 11,766,421Granted
  • Pharmaceutical Kits And Their Use For Treating Dry Eye DiseaseSep 7, 2023 · Application 18131841Pending
  • Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone For The Treatment Of Ocular DisordersMay 25, 2023 · Application 18100505Pending
  • Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseMay 12, 2022 · Application 17582627Pending
  • Use Of Chondroitin Sulfate For Relieving Ocular PainApplication 63186747Pending
  • Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseApplication PCTUS2019064371Pending
  • Eye Drop Formulations Containing Chondroitin Sulfate For Relieving Ocular Pain Or DiscomfortApplication PCTUS2025024021Pending
  • Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone For The Treatment Of Ocular DisordersApplication PCTUS2023011351Pending
  • Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone Sodium Phosphate For The Treatment Of Ocular DisordersApplication 63415419Pending
  • Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone Sodium Phosphate For The Treatment Of Ocular DisordersApplication 63402704Pending
  • Use Of Chondroitin Sulfate For Relieving Ocular PainApplication PCTUS2022027177Pending
  • Topical Application Of Mycophenolic Acid And Betamethasone Sodium Phosphate For The Treatment Of Ocular Surface DiseaseApplication 63317770Pending
  • Pharmaceutical Kits And Their Use For Treating Dry Eye DiseaseApplication PCTUS2021053552Pending
  • Pandion TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • BRITEBIO, INC.Similar federal contract value in Biotech · null in contracts
  • LumaCyte, Inc.Similar federal contract value in Biotech · null in contracts
  • MethylGene Inc.Similar federal contract value in Biotech · null in contracts
  • OtonomySimilar federal contract value in Biotech · null in contracts
  • Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .